{"id":"NCT01231347","sponsor":"NantCell, Inc.","briefTitle":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination With Gemcitabine as First Line Therapy for Metastatic Adenocarcinoma of the Pancreas","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-04-07","primaryCompletion":"2012-12-12","completion":"2012-12-12","firstPosted":"2010-11-01","resultsPosted":"2024-07-16","lastUpdate":"2024-07-16"},"enrollment":800,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Adenocarcinoma of the Pancreas","Advanced Solid Tumors","Cancer","Cancer of Pancreas","Cancer of the Pancreas","Metastases","Metastatic Cancer","Metastatic Pancreatic Cancer","Pancreas Cancer","Pancreatic Cancer","Bone Metastases","Endocrine Cancer","Oncology","Oncology Patients","Solid Tumors","Advanced Malignancy"],"interventions":[{"type":"DRUG","name":"AMG 479","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"AMG 479","otherNames":[]},{"type":"DRUG","name":"gemcitabine","otherNames":["Gemzar"]}],"arms":[{"label":"Placebo + gemcitabine","type":"PLACEBO_COMPARATOR"},{"label":"AMG 479 12 mg/kg dose + gemcitabine","type":"EXPERIMENTAL"},{"label":"AMG 479 20 mg/kg + gemcitabine","type":"EXPERIMENTAL"}],"summary":"AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival. The primary purpose of the study is to determine if AMG 479 and gemcitabine improves overall survival as compared to placebo and gemcitabine.","primaryOutcome":{"measure":"Determine if the Treatment of AMG 479 at 12 mg/kg and/or 20 mg/kg in Combination With Gemcitabine Improves Overall Survival as Compared With Placebo in Combination With Gemcitabine in Subjects With Metastatic Adenocarcinoma of the Pancreas","timeFrame":"From randomization up to 20 months","effectByArm":[{"arm":"AMG 479 12 mg/kg Dose + Gemcitabine","deltaMin":7,"sd":null},{"arm":"AMG 479 20 mg/kg + Gemcitabine","deltaMin":7.1,"sd":null},{"arm":"Placebo + Gemcitabine","deltaMin":7.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":152,"countries":["United States","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Czechia","Denmark","Finland","France","Germany","Greece","Hong Kong","Hungary","Italy","Japan","Lithuania","Netherlands","Poland","Portugal","Romania","Russia","Serbia","Slovakia","Slovenia","South Korea","Spain","Sweden","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["25609246"],"seeAlso":["http://www.amgentrials.com","https://pubmed.ncbi.nlm.nih.gov/25609246/"]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":317},"commonTop":["Nausea","Neutropenia","Thrombocytopenia","Fatigue","Decreased Appetite"]}}